| __timestamp | Ligand Pharmaceuticals Incorporated | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12122000 | 46425000 |
| Thursday, January 1, 2015 | 13380000 | 81491000 |
| Friday, January 1, 2016 | 21221000 | 94291000 |
| Sunday, January 1, 2017 | 26887000 | 121827000 |
| Monday, January 1, 2018 | 27863000 | 160524000 |
| Tuesday, January 1, 2019 | 55908000 | 200000000 |
| Wednesday, January 1, 2020 | 59392000 | 275000000 |
| Friday, January 1, 2021 | 69012000 | 328100000 |
| Saturday, January 1, 2022 | 36082000 | 463800000 |
| Sunday, January 1, 2023 | 24537000 | 565000000 |
| Monday, January 1, 2024 | 731100000 |
Cracking the code
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Ligand Pharmaceuticals Incorporated have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Neurocrine Biosciences has consistently increased its R&D expenses, peaking in 2023 with a staggering 565% increase from its 2014 spending. This upward trend underscores Neurocrine's aggressive pursuit of new therapies and technologies. In contrast, Ligand Pharmaceuticals has shown a more fluctuating pattern, with its highest R&D expenditure in 2021, marking a 470% increase from 2014, before a notable decline in subsequent years.
These spending patterns reflect each company's strategic focus and market positioning, offering insights into their future growth trajectories and potential breakthroughs in the biotech sector.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Genmab A/S vs Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Summit Therapeutics Inc. and Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Dr. Reddy's Laboratories Limited and Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Pharming Group N.V. and Ligand Pharmaceuticals Incorporated
Comparing Innovation Spending: Veracyte, Inc. and Ligand Pharmaceuticals Incorporated